VC
IBRX icon

VarCov Co’s ImmunityBio IBRX Stock Holding History

VarCov Co’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$122K Buy
+13,906
New +$105K 0.05% 347
2026
Q1 		– Sell
-264,557
Closed -$524K – 497
2025
Q4 		$524K Buy
+264,557
New +$599K 0.21% 167

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

VarCov Co's IBRX Position: Q2 2026 in Review

VarCov Co opened a new position in ImmunityBio (IBRX) in Q2 2026: 13,906 shares worth $122K. The stake represents 0.05% of the portfolio and ranks #347 among its holdings. This is a return to the name: VarCov Co previously reported a position in IBRX as recently as Q4 2025.

VarCov Co first reported a position in IBRX in Q4 2025 and has held it in 2 quarters since. The position peaked at $524K in Q4 2025. 402 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • VarCov Co held 13,906 shares of ImmunityBio worth $122K as of Q2 2026.
  • ImmunityBio was a new VarCov Co position in Q2 2026.
  • ImmunityBio made up 0.05% of VarCov Co's portfolio in Q2 2026, its #347 holding.
  • VarCov Co first reported a position in ImmunityBio in Q4 2025 and has held it in 2 quarters since.
  • VarCov Co's ImmunityBio position peaked at $524K in Q4 2025.
  • 402 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on VarCov Co's 13F filing for Q2 2026, filed 14 Aug 2026.